当代老年人群左心室辅助装置结局:STS INTERMACS分析
基于INTERMACS数据库2010至2020年接受耐久性左心室辅助装置(LVAD)的成人患者,按年龄分层评估生存、功能结局与生活质量。老年患者LVAD后功能容量增加、生活质量改善与年轻患者相似,且并发症更少,但死亡率随年龄增加而升高。
要点
- 老年患者LVAD后生活质量改善与年轻患者相似。
- 卒中、装置故障或血栓及再住院随年龄增加而减少。
- 新型装置与晚期死亡率降低相关(HR 0.35)。
核心结论
- 老年患者LVAD与功能容量增加、生活质量改善相似及并发症更少相关。
研究设计与样本
- 回顾性队列研究,纳入INTERMACS数据库中2010年1月1日至2020年3月1日接受耐久性LVAD的成人患者。
- 中位随访15个月(IQR 6-32个月)。
主要发现
- 竞争结局分析显示死亡率(70% CI)为:<65岁34%(33%-34%),65-75岁54%(54%-55%),>75岁66%(64%-68%)。
- >75岁患者死亡率在研究期间有所改善。
- 新型装置与晚期死亡率降低相关(HR 0.35;95% CI 0.25-0.49)。
- 卒中、装置故障或血栓及再住院随年龄增加而减少(均P<0.01)。
- 6分钟步行距离中位数从0英尺(IQR 0-665英尺)增至1,065英尺(IQR 642-1,313英尺)(P<0.001),生活质量评分从40(IQR 15-60)改善至75(IQR 60-90)(P<0.001),所有年龄组均如此。
临床怎么用
- 老年患者选择LVAD时应综合评估,考虑其功能和生活质量获益及年龄相关死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival, functional outcomes, and quality of life after left ventricular assist device (LVAD) are ill-defined in elderly patients, and with new-generation devices. OBJECTIVES: This study sought to evaluate survival, functional outcomes, and quality of life after LVAD in contemporary practice. METHODS: Adults receiving durable LVADs between January 1, 2010, and March 1, 2020, were identified from the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) database. The primary outcome was adjusted survival; secondary outcomes included quality of life rated using a visual analogue scale (where 0 represents "worst health" and 100 "best health"); 6-minute walk distance; stroke; device malfunction; and rehospitalization, stratified by patient age. Median follow-up was 15 months (IQR: 6-32 months). RESULTS: The cohort comprised 68.9% (n = 16,808) patients aged <65 years, 26.3% (n = 6,418) patients aged 65-75 years, and 4.8% (n = 1,182) patients aged >75 years, who were predominantly male (n = 19,119, 78%) and on destination therapy (n = 12,425, 51%). Competing outcomes analysis demonstrated mortality (70% CIs) of 34% (33%-34%), 54% (54%-55%), and 66% (64%-68%) for patients aged <65, 65-75, and >75 years, respectively, which improved during the study in patients aged >75 years. Newer-generation devices were associated with reduced late mortality (HR: 0.35; 95% CI: 0.25-0.49). Stroke, device malfunction or thrombosis, and rehospitalizations decreased with increasing age (all P < 0.01). Median 6-minute walk distance increased from 0 feet (IQR: 0-665 feet) to 1,065 feet (IQR: 642-1,313 feet) (P < 0.001), and quality of life improved from 40 (IQR: 15-60) to 75 (IQR: 60-90) (P < 0.001) after LVAD in all age groups. CONCLUSIONS: In elderly patients, LVADs are associated with increased functional capacity, similar improvements in quality of life, and fewer complications compared with younger patients.
引用
- Emerson D, Chikwe J, Catarino P, et al. Contemporary Left Ventricular Assist Device Outcomes in an Aging Population: An STS INTERMACS Analysis. J Am Coll Cardiol. 2021. PMID: 34446160. doi:10.1016/j.jacc.2021.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。